Biomedical papers, 2014 (vol. 158), issue 3

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014, 158(3):428-432 | 10.5507/bp.2013.022

Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma

Ludek Raidaa, Tomas Papajika, Zuzana Rusinakovaa, Vit Prochazkaa, Edgar Fabera, Dana Cahovab, Pavel Tucekb, Karel Indraka
a Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Geoinformatics, Faculty of Science, Palacky University Olomouc

Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment.

Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and < 90%). Reduced RDI in two groups (90-99% and < 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared.

Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13).

Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients.

Keywords: Hodgkin lymphoma, primary treatment, chemotherapy, relative dose intensity, therapeutic outcome

Received: April 24, 2012; Accepted: March 20, 2013; Prepublished online: April 10, 2013; Published: September 30, 2014


References

  1. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 1964;35:1-111. Go to PubMed...
  2. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents. XIV. Further studies on certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 1965;45:5-28. Go to PubMed...
  3. Hasenclever D, Brosteanu O, Gerike T, Loeffler M. Modelling of chemotherapy: The effective dose approach. Ann Hematol 2001;80:89-94.
  4. Horning SJ, Hoppe RT, Breslin S, Barlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-7. Go to original source... Go to PubMed...
  5. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rüffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Dühmke E, Georgii A, Loeffler M. A new regimen for advanced Hodgkin's disease. Ann Oncol 1998;9:67-71. Go to original source... Go to PubMed...
  6. Hillinger SM, Herzig GP. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes. J Clin Invest 1978;61:1620-7. Go to original source... Go to PubMed...
  7. Heøman M, Pauèek B, Raida L, Mysliveèek M, Zapletalová J. Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin's lymphoma. Eur J Radiol 2007;64:432-38. Go to original source... Go to PubMed...
  8. Cox D. Regression models and life tables. J R Stat Soc (B) 1972;34:187-220.
  9. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957;53:457-81. Go to original source...
  10. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33. Go to PubMed...
  11. Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A, Grimfors G, Björkholm M. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003;88:438-44. Go to PubMed...
  12. Owadally WS, Sydes MR, Radford JA, Hancock BW, Cullen MH, Stenning SP, Johnson PW. Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol 2010;21:568-73. Go to original source... Go to PubMed...
  13. Lagarde P, Bonichon F, Eghbali H, de Mascarel I, Chauvergne J, Hoerni B. Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. Br J Cancer 1989;59:645-49. Go to original source... Go to PubMed...
  14. Diehl V, Franklin J, Pfreundshuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M. Standard and increased-dose BEACOPP chemotherapy compared with COPP-EBVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95. Go to original source... Go to PubMed...